Get in touch about GlobalData Company reports

Contact the team or request a demo to find out how our data can drive your business forward

ChemoCentryx Inc (ChemoCentryx) is a bio pharmaceutical company that discovers, develops and commercializes orally-administered therapeutics for the treatment of cancer, autoimmune diseases and inflammatory disorders. The company's pipeline product includes Avacopan, CCX559,CCX587 and CCX507. Its Avacopan a lead candidate is an orally-administered complement inhibitor of the complement C5a receptor (C5aR), for the treatment of anti-neutrophil cytoplasmic auto-antibody-associated vasculitis. ChemoCentryx also provide preclinical research for evaluating the effect of combination therapy with chemokine receptor and check point inhibitors. ChemoCentryx is headquartered in Mountain View, California, the US.

Gain a 360-degree view of ChemoCentryx Inc and make more informed decisions for your business Gain a 360-degree view of ChemoCentryx Inc and make more informed decisions for your business Register your interest
Headquarters United States of America

Address 835 Industrial Road, Suite 600, San Carlos, California, 94070


Telephone 1 650 2102900

No of Employees 178

Industry Pharmaceuticals and Healthcare

Revenue (2021) $32.2M

   

   

Gain access to our premium signals and make informed decisions for your business Gain access to our premium signals and make informed decisions for your business Register your interest

ChemoCentryx Inc premium industry data and analytics

40+

Clinical Trials

Determine ChemoCentryx Inc go-to-market proposition and gain insight into the company’s clinical operations, recruitment, and trial strategy.

30+

Pipeline Drugs

Identify which of ChemoCentryx Inc’s products will be commercialized, helping you to better contend with shifting product portfolios, and allowing you to stay one step ahead of the market.

20+

Catalyst Calendar

Proactively evaluate ChemoCentryx Inc’s catalyst impacts to stay ahead of the competition & improve corporate planning. Bolster business development with timely opportunities.

19+

Insights

Remove risk and uncertainty, gain a competitive edge and secure actionable leads with access to company-related investigative journalist content.

1

Marketed Drugs

Understand ChemoCentryx Inc’s commercialized product portfolio to stay one step ahead of the market.

1

ICT Spend & Tech Priorities

IT Client Prospector provides intelligence on ChemoCentryx Inc’s likely spend across technology areas enabling you to understand the digital strategy.

Products and Services

Products Services Brands
Pipeline Clinical Development Tavneos
Tavneos (Avacopan)
CCX559 / PD-1 / PD-L1 (Immuno-Oncology)
XYZ
XYZ
XYZ
Understand ChemoCentryx Inc portfolio and identify potential areas for collaboration Understand ChemoCentryx Inc portfolio and identify potential areas for collaboration Register your interest
Image for loader

Competitor Comparison

Key Parameters ChemoCentryx Inc Enzo Biochem Inc MediciNova Inc Aceragen Inc Assertio Therapeutics Inc
Headquarters United States of America United States of America United States of America United States of America United States of America
City San Carlos Farmingdale La Jolla Durham Lake forest
State/Province California New York California North Carolina Illinois
No. of Employees 178 125 6 - -
Entity Type Private Private Public Private Private
Benchmark the company against the market with exclusive information on key competitors Benchmark the company against the market with exclusive information on key competitors Register your interest
Executives
Name Position Board Since Age
Thomas J. Schall Chief Executive Officer; President; Chairman Executive Board 2012 62
Rita Jain Director; Senior Vice President; Chief Medical Officer Executive Board 2019 59
Tausif Butt Chief Operating Officer; Executive Vice President Senior Management 2021 56
Kari E. Leetch Senior Vice President - Human Resources Senior Management - -
Markus J. Cappel Chief Business Officer and Treasurer Senior Management 2007 61
Non Dignissim Eros Proin vel Convallis 2026 XY
Non Dignissim Eros Proin vel Convallis 2026 XY
Non Dignissim Eros Proin vel Convallis 2026 XY
Gain insight into ChemoCentryx Inc key executives to enhance your sales strategy Gain insight into ChemoCentryx Inc key executives to enhance your sales strategy Register your interest
Still looking?

Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.

Explorer

Access more premium companies when you subscribe to Explorer

Why are you leaving?